Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
GEN1d
Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
Medical Xpress4d
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won't be rejected by the patient receiving them and will persist in fighting the cancer.
News Medical4d
New findings could make off-the-shelf CAR T cell therapy a reality
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won't be rejected by the patient receiving them and will persist in fighting the cancer.
EurekAlert!5d
New MSK research a step toward off-the-shelf CAR T cell therapy for cancer
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won’t be rejected by the patient receiving them and will persist in fighting the cancer.